The virtual international stroke trials archive

Stroke

Volumn 38, Issue 6, 2007, Pages 1905-1910

  Ali, Myzoon ^a   Bath, Philip M W ^b   Curram, John ^c   Davis, Stephen M ^d   Diener, Hans Christoph ^e   Donnan, Geoffrey A ^d   Fisher, Marc ^f   Gregson, Barbara A ^g   Grotta, James ^h   Hacke, Werner ⁱ   Hennerici, Michael G ^j   Hommel, Marc ^k   Kaste, Markku ^l   Marler, John R ^m   Sacco, Ralph L ⁿ   Teal, Philip ^o   Wahlgren, Nils Gunnar ^p   Warach, Steven ^m   Weir, Christopher J ^q   Lees, Kennedy R ^a,r  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c Bayer plc UK   (United Kingdom)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k UNIV GRENOBLE ALPES   (France)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

ⁿ Och Spine at New York Presbyterian Hospitals   (United States)

^o UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^p KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^q UNIVERSITY OF GLASGOW   (United Kingdom)

^r Gardiner Institute   (United Kingdom)

more..

Author keywords

Clinical trials; Database; Modified Rankin Scale; National Institutes of Health Stroke Scale; Natural history; Trial design

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ALTEPLASE; ANCROD; CITICOLINE; CLOMETHIAZOLE; DISUFENTON SODIUM; GAVESTINEL; LUBELUZOLE; MAGNESIUM SULFATE; NIMODIPINE; REPINOTAN; STREPTOKINASE; TINZAPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ANAMNESIS; ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DATA BASE; HUMAN; INFORMATION CENTER; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; STROKE; TREATMENT PLANNING; VIRTUAL INTERNATIONAL STROKE TRIALS ARCHIVE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARCHIVES; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 34249813726     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.473579     Document Type: Article

References (33)

1. Carter K, Anderson C, Hacket M, Feigin V, Barber PA, Broad JB, Bonita R, on behalf of the Auckland Regional Community Stroke (ARCOS) Study Group. Trends in ethnic disparities in stroke incidence in Auckland, New Zealand, during 1981 to 2003. Lancet Neurol. 2006;5:130-139.
2. American Stroke Association. What is stroke? Available at http://www.strokeassociation.org/presenter.jhtml?identifier=2528. Last accessed November 5, 2004.
3. Haidinger G, Waldhoer T, Tuomilehto J, Vutuc C. Assessment of costs relating to hospitalisation of stroke patients in Austria for 1992 and prospective costs for the year 2010. Cerebrovasc Dis. 1997;7:163-167.
4. Marler J; for the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
5. Sherman DG, Levy DE. Outcomes of ancrod in acute ischaemic stroke. JAMA. 2000;284:1926-1927.
6. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Rivera F. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial: Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
7. Muir K. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design. Stroke. 2002;33:1545-1550.
8. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T, for the Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
9. Bogousslavsky J, Kaste M, Olsen TS, Hacke W, Orgogozo JM. Risk factors and stroke prevention. Cerebrovasc Dis. 2000;10(suppl 3):12-21.
10. Hatano S. The WHO Collaborative Study on the Control of Stroke in the Community. WHO Bull. 2006;54:541-553.
11. http://www.vista.gla.ac.uk/charter.aspx. Last accessed August 20, 2006.
12. www.vista.gla.ac.uk/index.aspx Last accessed August 20, 2006.
13. MacLeod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004;35:1203-1208.
14. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
15. Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE, for the Citicoline Stroke Study Group. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 1999;30:2592.
16. Young FB, Lees KR, Weir CJ. Strengthening acute stroke trials through optimal use of disability end points. Stroke. 2003;34:2676-2680.
17. Ravina B, Janis S, Keleti J, Marler JM. Funding evidence: The National Institute of Neurological Disorders and Stroke clinical trials program. J Am Soc Exp Neurother. 2006;1:317-322.
18. Prosser J, MacGregor L, Lees KR, Diener HC, Hacke W, Davis S, on behalf of the VISTA investigators. Predictors of early cardiac morbidity and mortality after ischemic stroke. Stroke. In press.
19. Weimar C, Roth MP, Zillessen G, Glahn J, Wimmer ML, Busse O, Haberl RL, Diener HC, for the German Stroke Databank Collaborators. Complications following acute ischaemic stroke. Eur Neurol. 2002;48:133-140.
20. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E, on behalf of the CLASS-I/H/T Investigators. Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I). Stroke. 2002;33:122-129.
21. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne M-H, Hennerici M. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
22. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan GA, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke. Lancet. 1998;352:1245-1251.
23. Sacco RL, De Rosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JLP, for the GAIN Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA. 2001;285:1719-1728.
24. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M, Orgogozo JM, Whitehead J, for the GAIN International Steering Committee and Investigators. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet. 2000;355:1949-1954.
25. Lees KR, Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): randomised controlled trial. Lancet. 2004;363:439-445.
26. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal PJ, Wessel T, on behalf of the LUB-INT-13 Investigators. Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke. 2000;31:2543-2551.
27. Wahlgren NG, MacMahon DG, De Keyser J, Indredavik B, Ryman T, for the INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis. 1994;4:204-210.
28. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J, for the ASSIST Investigators. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke. 2000;31:347-354.
29. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil J, Rosen D, Stewart-Wynn EG, Tuck RR. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA. 1996;25:961-966.
30. Bath PMW, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J-E, O'Neill D, Orgogozo JM, Ringelstein B, van der Sande J-J, Turpie AGG, for the TAIST Investigators. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001;358:702-710.
31. Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Bueker-Nott H, Rother J, Neundoerfer B, Kolominsky-Rabas PL, and the German Stroke Registers Study Group. Frequency of thrombolytic therapy in patients with acute ischemic stoke and the risk of in-hospital mortality. Stroke. 2003;34:1106-1113.
32. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MDM, Barer DH, for the STICH Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387-397.
33. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM, for the ESTAT investigators. Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomized controlled trial. Lancet. 2006;368:1871-1878.